User:Mr. Ibrahem/Cetuximab
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | EGF receptor |
| Clinical data | |
| Trade names | Erbitux |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Epidermal growth factor receptor (EGFR) inhibitor[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 114 hrs |
| Chemical and physical data | |
| Formula | C6484H10042N1732O2023S36 |
| Molar mass | 145781.92 g·mol−1 |
  (what is this?) (verify) | |
Cetuximab, sold under the brand name Erbitux, is a medication used to treat colorectal cancer and head and neck cancer.[1] For colon cancer it is for metastatic disease that is EGFR positive and without RAS gene mutation.[2] It is given by injection into a vein.[2]
Common side effects include rash, low magnesium, mouth inflammation, and liver problems.[2] Other side effects include infusion reactions.[1] Use in pregnancy may harm the baby.[1] It is a monoclonal antibody and epidermal growth factor receptor (EGFR) inhibitor.[1]
Cetuximab was approved for medical use in Europe and the United States in 2004.[2][1] In the United Kingdom 500 mg costs the NHS about £890 as of 2021.[3] In the United States this amount is about 3,600 USD.[4]
References[edit]
- ^ a b c d e f g "DailyMed - ERBITUX- cetuximab solution". dailymed.nlm.nih.gov. Archived from the original on 20 October 2021. Retrieved 3 January 2022.
- ^ a b c d e "Erbitux". Archived from the original on 14 May 2021. Retrieved 3 January 2022.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 913. ISBN 978-0857114105.
- ^ "Erbitux Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 4 February 2021. Retrieved 3 January 2022.